Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Viral particles as immunogens against enterovirus infection and their manufacture

A technology of virus particles, enteroviruses, applied to the immune response of diseases caused by them, hand, foot and mouth disease. , induced anti-enteroviral infection field

Active Publication Date: 2021-01-26
NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH +1
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For CVA6 and CVA10, no previous studies have reported the availability of suitable cell lines for the production of viral particles for human vaccine manufacture

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Viral particles as immunogens against enterovirus infection and their manufacture
  • Viral particles as immunogens against enterovirus infection and their manufacture
  • Viral particles as immunogens against enterovirus infection and their manufacture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0113] Example 1: Ideas for developing a HFMD vaccine with multivalent immunogenic components

[0114] A serum-free, Vero cell-based, formalin-inactivated whole-virus EV71 vaccine has been developed and has undergone human clinical trials (Wu et al., 2004; Liu et al., 2007; Liu et al. al., 2011; Chang et al., 2012; Chou et al., 2012; Li et al., 2012; Cheng et al., 2013; Zhu et al., 2013). Surprisingly, unexpected results showed that EV71 vaccine failed to protect against CVA16 infection in cell culture assays (Chou et al., 2013). Our recent studies on the CVA16 vaccine candidate also showed that mouse and rabbit anti-CVA16 antisera were unable to neutralize EV71 (Chong et al., 2012). When the protein sequences of these virus strains ((EV71, CVA6, CVA10 and CVA16) were arranged and analyzed; the similarity of the P1 peptide was found to be 65-80% on the P1 sequence (Table 1). HFMD caused by common enterovirus strains (such as CVA6 and CVA10) is urgently needed to develop a HF...

Embodiment 2

[0117] Example 2: Establishment of a Novel Biological Process for Kexakivirus Group A

[0118] Biological processes for the manufacture of human multivalent HFMD vaccines have been developed and explored. Based on the existing biological process for the development of EV71 vaccine described in published literature (Liu et al., 2007; Chou et al., 2012), to our surprise, CVA6 and CVA10 can be expressed in Infect and replicate in RD cells, but unable to infect and replicate in Vero cells ( figure 1 ). However, RD cells are not as suitable for production of human vaccines as HEK293 cells. Please refer to Table 2 and Table 3 at the same time.

[0119] Table 2: Viral titers of enteroviruses produced in different cells

[0120] Virus potency (TCID50 / mL)

[0121]

[0122]

[0123] CPE: cytopathic effect

[0124] In order to confirm that no viral protein can be expressed and produced in Vero cell culture, two monoclonal antibodies (N1 and MAB979 can specifically recognize VP1...

Embodiment 3

[0125] Example 3: Using HEK293 cell culture to produce virus

[0126] Since CVA6 and CVA10 cannot infect Vero cells and RD cells and cannot be used for human vaccine production, other possible GMP-certified cell lines, such as MDCK, MRC-5, CHO and HEK293, were tested and used for propagation CVA6 and / or CVA10. To our surprise, both CVA6 and CVA10 could only infect HEK293 cells ( image 3 ).

[0127] To obtain sufficient CVA6 and CVA10 for analysis of biochemical and immunogenic properties, the viruses were cultured in HEK293 cells. After 6 days of culture, the cell density reached 1-2.5×10 per mL 6 cell. cells at an MOI of 10 -2 to 10 -5 concentration for infection. Viruses were harvested and collected from cell culture supernatants at 6 days post infection (DPI). See Table 3.

[0128] Table 3: Viral titers of enteroviruses produced in HEK293 cells

[0129] Virus price

[0130]

[0131] CPE: cytopathic effect

[0132] When EV71 infects HEK293 cells, the virus ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to a virus particle as an immunogen against enterovirus infection and its production method. In particular, the invention features the use of human embryonic kidney 293 (HEK293) cells to produce enterovirus A virus particles, specifically kexackievirus A6 (CVA6) particles, or kexackievirus A10 (CVA10 ) particles, or both, and other optional Enterovirus A virus particles, such as Kexackievirus A16 (CVA16), and / or Enterovirus A71 (EV71). Surprisingly, the harvested virus particles in HEK293 cells were quite high and could effectively induce immune responses against enterovirus infection, especially for CVA6 and CVA10. The present invention also relates to a human immune composition against enterovirus infection, comprising the virus particles as described herein, and a method for preventing enterovirus infection or the diseases caused by it, specifically hand, foot and mouth disease ( Hand-Food-Mouth disease; HFMD), the method is by administering the immune composition to an individual in need.

Description

technical field [0001] The present invention relates to a virus particle as an immunogen against enterovirus infection, and a method for producing the virus particle by using human embryonic kidney 293 (HEK293) cells. The present invention also relates to a human immune composition against enterovirus infection, and a method of inducing an immune response against enterovirus infection or a disease caused by it, specifically hand, foot and mouth disease (HFMD). Background technique [0002] Enteroviruses, belonging to the picornaviridae family, are small, non-enveloped viruses containing positive-sense RNAs. The genus Enterovirus currently includes 12 species: Enterovirus A, Enterovirus B, Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus J, Rhinovirus A, Rhinovirus B, and rhinovirus C. Infection of the intestinal tract by these viruses can cause various types of diseases. Typical enteroviral diseases are meningitis, para...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10A61K39/125A61K39/295A61P31/14C07K14/085C12N7/00C12N7/04
CPCA61K39/12A61K2039/5258A61P31/14C07K16/1009C07K2317/33C07K2317/76C12N7/00C12N2770/32334C12N2770/32351
Inventor 庄再成刘家齐林小瑜周彦宏
Owner NAT INST OF HEALTH REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com